Author's response to reviews

Title: Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial

Authors:

Xianghua Huang (hxhszb@163.com)
Qingwen Wang (1960wqw@medmail.com.cn)
Wencui Chen (chenwencui315@163.com)
Caihong Zeng (zengch_nj@hotmail.com)
Zhaohong Chen (czh4@sina.com)
Dehua Gong (gong_doctor@126.com)
Haitao Zhang (htzhang163@163.com)
Zhihong Liu (zhihong--liu@hotmail.com)

Version: 5
Date: 1 December 2013

Author's response to reviews: see over
Dear Dr. Denyer,

Re: Manuscript “Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial”

Please accept for your editorial consideration this submission of our revised manuscript to the BMC Medicine.

Thank you and the reviewers for their comments on the previous version. We have revised the manuscript carefully according to your editorial requests. All revisions are highlighted in red font. First, this clinical trial is registered at clinicaltrials.gov as NCT01998503, and the registration information can be found on the website http://www.clinicaltrials.gov/ct2/show/NCT01998503. We have added the trial registration number in our manuscript (page 4, line 6-7). Second, we have added a comment about the sample size to the limitation section of our discussion as “Fourth, the sample size of this trial is too small to allow patients stratification based on known risk factors, as well as to allow a subgroup analysis, so the results for stratification or subgroup analysis can’t match other studies’ results. We will continue this study and enroll more patients to make this stratification or subgroup analysis more clear.” (page 19, line 19-22).

We hope this version answers all the questions and get accepted for publication by the BMC Medicine. We have no conflict of interest to declare.

I look forward to hearing from you.

Yours sincerely,

Zhihong Liu, M.D.
Professor of Medicine
Academician, Chinese Academy of Science & Engineering
President of Chinese Society of Nephrology
Director
Research Institute of Nephrology
Jinling Hospital
Nanjing University School of Medicine
E-mail: zhihong--liu@hotmail.com